Antioxidant Effects of Bidens Pilosa Extract Protect RAW 264.7 Cells from Cisplatin-induced Cytotoxicity.

IF 1.7 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-08-01 DOI:10.21873/anticanres.17707

Kihiro Shimizu, Ako Kudo, Toko Iida, Keisuke Sato, Akifumi Nakata, Kenichi Komatu, Kazuki Takai, Koji Wakame

{"title":"Antioxidant Effects of Bidens Pilosa Extract Protect RAW 264.7 Cells from Cisplatin-induced Cytotoxicity.","authors":"Kihiro Shimizu, Ako Kudo, Toko Iida, Keisuke Sato, Akifumi Nakata, Kenichi Komatu, Kazuki Takai, Koji Wakame","doi":"10.21873/anticanres.17707","DOIUrl":null,"url":null,"abstract":"Background/aim: Bidens pilosa (BP) is a medicinal plant that exerts antioxidant and antiallergic effects and is used to treat various diseases. Cisplatin (CDDP) is used for a variety of malignancies, but its use is limited by its side effects. In this study, the effect of BP on reducing CDDP toxicity was examined using RAW264.7 cells, which are normal macrophages.Materials and methods: RAW 264.7 cells were treated with BP and cytotoxicity and antioxidant capacities were measured. RAW 264.7 cells were treated with CDDP with and without BP. The expression of antioxidant-related genes was measured by RT-PCR, whereas apoptosis and reactive oxygen species (ROS) were assessed by flow cytometry.Results: BP inhibited CDDP-induced cytotoxicity in RAW 264.7 cells. Antioxidant gene expression was significantly increased in cells treated with BP and CDDP. BP reduced intracellular ROS as well as the percentage of apoptotic cells in RAW 264.7 cells treated with BP and CDDP.Conclusion: BP reduces CDDP-induced cytotoxicity; these effects are the result of the antioxidant activity of BP.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 8","pages":"3459-3467"},"PeriodicalIF":1.7000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17707","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Bidens pilosa (BP) is a medicinal plant that exerts antioxidant and antiallergic effects and is used to treat various diseases. Cisplatin (CDDP) is used for a variety of malignancies, but its use is limited by its side effects. In this study, the effect of BP on reducing CDDP toxicity was examined using RAW264.7 cells, which are normal macrophages.

Materials and methods: RAW 264.7 cells were treated with BP and cytotoxicity and antioxidant capacities were measured. RAW 264.7 cells were treated with CDDP with and without BP. The expression of antioxidant-related genes was measured by RT-PCR, whereas apoptosis and reactive oxygen species (ROS) were assessed by flow cytometry.

Results: BP inhibited CDDP-induced cytotoxicity in RAW 264.7 cells. Antioxidant gene expression was significantly increased in cells treated with BP and CDDP. BP reduced intracellular ROS as well as the percentage of apoptotic cells in RAW 264.7 cells treated with BP and CDDP.

Conclusion: BP reduces CDDP-induced cytotoxicity; these effects are the result of the antioxidant activity of BP.

查看原文本刊更多论文

毛缕草提取物对顺铂诱导的RAW 264.7细胞的抗氧化作用

背景/目的：毛拜登（Bidens pilosa， BP）是一种具有抗氧化和抗过敏作用的药用植物，用于治疗多种疾病。顺铂（CDDP）用于多种恶性肿瘤，但其使用受到其副作用的限制。本研究采用正常巨噬细胞RAW264.7细胞检测BP对CDDP毒性的降低作用。材料和方法：采用BP处理RAW 264.7细胞，测定细胞毒性和抗氧化能力。分别用CDDP处理RAW 264.7细胞，有BP和无BP。RT-PCR检测抗氧化相关基因的表达，流式细胞术检测细胞凋亡和活性氧（ROS）的表达。结果：BP可抑制cddp诱导的RAW 264.7细胞毒性。BP和CDDP处理后细胞抗氧化基因表达显著升高。BP和CDDP联合处理的RAW 264.7细胞中，BP可降低细胞内ROS和凋亡细胞百分比。结论：BP可降低cddp诱导的细胞毒性；这些作用是BP抗氧化活性的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.